Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1

Gifford, F.J. and Morling, J.R. and Fallowfield, J.A. (2017) Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Alimentary Pharmacology and Therapeutics . ISSN 1365-2036

[img] PDF - Repository staff only until 4 January 2018. - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (1MB)

Abstract

Background

Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a very poor prognosis. There is a significant unmet need for a widely approved, safe and effective pharmacological treatment.

Aim

To re-evaluate efficacy and safety of pharmacological treatments for HRS1, in the light of recently published randomised controlled trials (RCTs).

Methods

MEDLINE (OvidSP), EMBASE, PubMed and Cochrane registers were searched for RCTs reporting efficacy and adverse events related to pharmacological treatment of HRS1. Search terms included: ‘hepatorenal syndrome’, ‘terlipressin’, ‘noradrenaline’, ‘octreotide’, ‘midodrine’, ‘vasopressin’, ‘dopamine’, ‘albumin’ and synonyms. Comparison of vasoactive drugs vs. placebo/no treatment, and two active drugs were included. Meta-analysis was performed for HRS1 reversal, creatinine improvement, mortality and adverse events.

Results

Twelve RCTs enrolling 700 HRS1 patients were included. Treatment with terlipressin and albumin led to HRS1 reversal more frequently than albumin alone or placebo (RR: 2.54, 95% CI: 1.51–4.26). Noradrenaline was effective in reversing HRS1, but trials were small and nonblinded. Overall, there was mortality benefit with terlipressin (RR: 0.79, 95% CI: 0.63–1.01), but sensitivity analysis including only trials with low risk of selection bias weakened this relationship (RR: 0.87, 95% CI: 0.71–1.06). Notably, there was a significant risk of adverse events with terlipressin therapy (RR: 4.32, 95% CI: 0.75–24.86).

Conclusions

Terlipressin treatment is superior to placebo for achieving HRS1 reversal, but mortality benefit is less clear. Terlipressin is associated with significant adverse events, but infusion regimens may be better tolerated. There is continued need for safe and effective treatment options for hepatorenal syndrome.

Item Type: Article
Additional Information: This is the peer reviewed version of the following article: Gifford, F. J., Morling, J. R. and Fallowfield, J. A. (2016), Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. Aliment Pharmacol Ther., which has been published in final form at http://dx.doi.org/10.1111/apt.13912. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
Keywords: Hepatorenal syndrome, Vasoactive drugs, Terlipressin, Noradrenaline, Systematic review, Meta-analysis.
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Epidemiology and Public Health
Identification Number: https://doi.org/10.1111/apt.13912
Depositing User: Eprints, Support
Date Deposited: 09 Jan 2017 13:30
Last Modified: 09 Jan 2017 14:32
URI: http://eprints.nottingham.ac.uk/id/eprint/39691

Actions (Archive Staff Only)

Edit View Edit View